SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Omeros
OMER 7.195-1.8%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Julius Wong who wrote (416)7/2/2017 6:17:38 PM
From: Biotech Jim3 Recommendations

Recommended By
Howard Williams
scaram(o)uche
sjemmeri

  Read Replies (3) of 464
 
My view is that OMER would be wasting its time in pursuit of the alleged slanderer. There best defense against this short seller is offense, specifically to bring forward more news on study/pipeline progress.

Like the following. This link to clintrials.gov shows that the company just updated its currently recruiting Ph3 trial, titled Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS).

clinicaltrials.gov


Did not short seller Doyle claim that the company does not have any Ph3 trial ongoing with OMS 721?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News